LiDCO Group Plc

("LiDCO" or the "Company")

                                                                                Notice of Patent Acceptance

LiDCO Group Plc (AIM:LID), the cardiovascular monitoring company, announces that the US Patent Office has issued a notice of acceptance for a US patent protecting the Graphical User Interface ("GUI") of the LiDCOrapid^v2 monitor which displays both hemodynamic status and depth of anaesthesia in a single unit. The USA is the world's largest market for hemodynamic and depth of anaesthesia monitoring of patients during surgical procedures.

LiDCO's GUI makes the touch-screen monitor more easily interpretable than multiple monitor displays in the surgical setting due to the distinctive display of hemodynamic parameters and depth of anaesthesia. This GUI is one of the screens integrated into the new LiDCOrapid ^v2 with Unity software which is now available in the USA following FDA clearance.

LiDCO already has patents in Japan and the EU for the GUI screen used in the basic LiDCOrapid monitor, with a US patent grant pending and expected to complete shortly. Patents for the combined multi parameter display are pending in Japan and the EU.

Terry O'Brien, Chief Executive Officer of LiDCO, commented: "The granting of a patent covering our GUI for combined depth of anaesthesia and hemodynamic multi parameter monitoring is a further major step in protecting our innovations in user display technology. This clear-cut user interface greatly helps users with the task of simultaneously monitoring anaesthetics, fluids and cardiac output with the intent of optimising surgical outcomes in high risk patients."

The Company will announce its interim results for the six months ended 31 July 2013 on Tuesday, 1 October 2013.

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:

·    early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·    quantification of hemodynamic response

·    guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BIS^TM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

*BIS^TM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

* CNAP^TM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.